Pooled data from 268 patients in two Phase 3 trials evaluating Acadia Pharmaceuticals' (ACAD +2.4%) Nuplazid (pimavanserin) for the treatment of Parkinson's disease (PD) psychosis show a substantial benefit versus placebo. The improvement in psychosis, measured by the SAPS-PD scale, is highly statistically significant (p<0.001). The data were presented at the 19th International Congress of Parkinson's Disease and Movements Disorders in San Diego, CA.
Pimavanserin is a small molecule selective serotonin inverse agonist that targets receptors, called 5-HT2A, that play a key role in psychosis.
PD affects as many as 6M people worldwide with about 40% (2.4M) experiencing psychosis. There are no approved treatments for the condition.
The company plans to submit a New Drug Application (NDA) for Nuplazid for PD psychosis later this year.
Subscribe for full text news in your inbox